It is estimated that severe asthma affects between 5% and 10% of people with asthma. Patients with severe asthma often require the care of a specialist and intensive care.
Although biological therapies have been shown to reduce the risk of degeneration associated with severe uncontrolled asthma and use them more and more, little is known about data in the world that indicates the use in patients with subarachnoid hemorrhage with severe asthma.
The CHRONICLE clinical trial is an ongoing observational study that incorporates real-world data on the pattern of patients 18 years of age or older stopping, changing, and continuing to use biology in the extreme asthma asthma. Patients had to receive monoclonal antibody therapy, systemic corticosteroid, or other systemic immunosuppressants for 50% or more in the previous year.
Researchers compared clinical features and asthma-related outcomes for patients enrolled from February 2018 through February 2020 who moved from 1 biologist to another, discontinued biological treatment, or continuous biological use. Data were collected at the time of study recording and updated every 6 months.
Of the 1884 patients enrolled, 1294 (69%) used at least 1 biologist during the study period. In total, 1494 biology uses were recorded for 5 biology:
- omalizumab (44%)
- mepolizumab (24%)
- benralizumab (21%)
- dupilumab (8%)
- reslizumab (3%)
There were 134 switches, 101 stops, and 1222 follow-ups, with several of the 1294 patients eligible for more than 1 category of biological practice. More than 90% of patients with severe asthma continued to have a biologist take a biologist during the last data collection compared to 10% of patients who turned biology and 8% stop patients.
Patients who stopped biology were diagnosed with severe asthma at a younger age, were less likely to get a full-time job, more likely to have Medicaid insurance, and more likely to live in areas urban patients who continued to use a biologist or turned to another biologist.
These patients were also more frequently treated by a pulmonologist, more likely to have a asthma-related disability, had more sustained systemic corticosteroid use, and had a lower quality of life as indicated by lower scores for the St George’s Breathing Questionnaire.
Patients who transferred from one biological to another were found to have a higher incidence of nasal or sinus polyps and sensitivity to nonsteroidal drugs with anti-inflammatory effects.
Researchers noted that the most commonly reported reasons for switching from or discontinuing biological therapy are reduced asthma, reduced medication efficacy, and medication ineffectiveness. .
The researchers noted that patients who followed biological use at the time of enrollment appeared to have better disease control, suggesting that patients with less asthma control at baseline may not see a benefit with biological therapy. For these patients, more therapeutic options may need to be explored in the future.
Information
Soong W, Ambrose CS, Carstens D, Trudo F, Moore WC, Panettieri RA. What major asthma patietns modify, stop, or follow biological treatments? Presented at the 2021 Academy of Allergy, Asthma & Immunology AGM, February 26 – March 1, 2021; Poster 178.